Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 8/20 | 0.51 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.39 |
| ▸ | CTPS1 | P17812 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458702 | 0.85 | PTGER2 (0.46) | PTGER2 | |
| SCHEMBL17472561 | 0.83 | PTGER2 (0.65) | PTGER2SLC13A5RXRARXRB | |
| SCHEMBL3459169 | 0.77 | PTGER2 (0.41) | PTGER2 | |
| SCHEMBL28054731 | 0.77 | PTGER2 (0.45) | PTGER2SLC13A5CTPS1RXRARXRB | |
| SCHEMBL17472578 | 0.77 | PTGER2 (0.46) | PTGER2SLC13A5CTPS1RXRARXRB | |
| SCHEMBL17940643 | 0.76 | PTGER2 (0.54) | PTGER2SLC13A5CTPS1RXRARXRB | |
| SCHEMBL17472563 | 0.76 | PTGER2 (0.65) | PTGER2 | |
| SCHEMBL17472672 | 0.76 | PTGER2 (0.68) | PTGER2 | |
| SCHEMBL17472577 | 0.76 | PTGER2 (0.45) | PTGER2SLC13A5CTPS1RXRARXRB | |
| SCHEMBL17472595 | 0.74 | PTGER2 (0.66) | PTGER2SLC13A5CTPS1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676720-B2 | Substituted biaryl compound | UBE INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2980075-A1 | SUBSTITUTED BIARYL COMPOUND | UBE Industries, Ltd. (JP) | 2016-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | FIBP, FGF2, FGFR2 | PTGER2 2670/4885SLC13A5 1176/4885CTPS1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.